Results 281 to 290 of about 436,330 (367)

Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study. [PDF]

Acta Derm Venereol
Schlösser AR, Caron AGM, Den Ouden MS, Baart SJ, Gerbens LAA, Spuls PI, Nijsten TEC, Schappin R, Hijnen D.   +8 more
europepmc   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012-2023. [PDF]

PLoS One
Zhong X, Luo J, Huang Y, Wang S, Huang Y.   +4 more
europepmc   +1 more source

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker, C. F. den Hartog Jager, Marlies de Graaf, Marjolein S. de Bruin‐Weller, Femke van Wijk, Edward F. Knol   +7 more
wiley   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

International Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo, Luca Mastorino, Luca Cangialosi, Davide Favre, Chiara Anna Fiasconaro, Yingying Liao, Federico Goso, Niccolò Siliquini, Giovanni Cavaliere, Pietro Quaglino, Simone Ribero, Michela Ortoncelli   +11 more
wiley   +1 more source

Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study. [PDF]

Cureus
Aldebei A, Hammouri YS, Abdallat SA, Hjazeen A, Muhanna AM, Arnous H, Alshwayyat R, Alkotob M.   +7 more
europepmc   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Janus Kinase Inhibitors As Emerging Therapy in the Treatment of Psoriatic Arthritis: A Narrative Review of Efficacy, Safety, and Future Perspective. [PDF]

Cureus
Barsoum M, Mohamed M, Ibrahim A, Khalfalla A, Elbashir L.   +4 more
europepmc   +1 more source

Signal Transducer and Activator of Transcription (STAT) Proteins Regulate Mucosal‐Associated Invariant T (MAIT) Cell Function

Immunology, EarlyView.
Integrated transcriptomic, proteomic and flow cytometry analyses reveal that STAT1 negatively regulates MAIT cell effector and glycolytic functions, while STAT3, STAT5 and HIF1α act as positive modulators. Targeting these pathways may offer new strategies to restore MAIT cell function in immune dysregulation and cancer.
Olivia J. Cheng, Eimear K. Ryan, Michael Bennett, Christy Clutter, Jackson G. Cacioppo, Jeffrey Aubé, Andy E. Hogan, Daniel T. Leung   +7 more
wiley   +1 more source

Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease. [PDF]

J Crohns Colitis
Su J, Lartey DA, Zanella G, Hawinkels LJAC, Matteoli G, Löwenberg M, Barnhoorn MC.   +6 more
europepmc   +1 more source